About Dong-A Socio Holdings
Dong-A Socio Holdings is a company based in Seoul (South Korea) founded in 1932. The company has 82 employees. Dong-A Socio Holdings operates in a competitive market with competitors including BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and ALX Oncology, among others.
- Headquarter Seoul, South Korea
- Employees 82
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website donga.co.kr/main/main?lang=ko
- Social LinkedIn X Instagram YouTube
- Legal Name Dong-A Socio Holdings Co., Ltd.
- Annual Revenue₹2.08 Cr
FY 2025 · -12% YoY
- Net Profit₹0.03 Cr
FY 2025 · 2% margin
- EBITDA₹0.27 Cr
FY 2025 · 13% margin
- Employee Count82
Associated legal entities of Dong-A Socio Holdings
Dong-A Socio Holdings operates through Dong-A St India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Dong-A St India Private Limited CIN U33201MH2021FTC355665 | Active | 22 Feb 2021 | Mumbai, Maharashtra | ₹2.1 Cr | – | 2 | View details |
Apps and channels of Dong-A Socio Holdings
its YouTube channel 동아쏘시오그룹 has 39.9K subscribers and 30 videos.
Videos from Dong-A Socio Holdings
The most watched videos on Dong-A Socio Holdings's YouTube channel, 동아쏘시오그룹 (39.9K subscribers). Click a video to play it here.
More on 동아쏘시오그룹.
Board of directors of Dong-A St India Private Limited (Dong-A Socio Holdings)
Dong-A St India Private Limited is the primary company behind Dong-A Socio Holdings. The board of Dong-A St India Private Limited currently have 2 directors; the longest-serving is Daewon Kwak, appointed in 2021. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Daewon Kwak DIN 09076873 | Director | 22 Feb 2021 | 5 yrs 7 mo | Dong-A St India Private Limited |
| Sungkyu Park DIN 09076875 | Director | 22 Feb 2021 | 5 yrs 7 mo | Dong-A St India Private Limited |
People of Dong-A Socio Holdings
4 people are tracked at Dong-A Socio Holdings (4 in leadership); the tracked headcount is 82.
| Name | Role | Group |
|---|---|---|
Matthew Han | CEO | Leadership |
Eun-Ju Ryu | COO Dong-a America Co. Head Of Open Innovation Dong-a ST USA | Leadership |
Jae Hun Jung | CEO | Leadership |
Shin Sofia | Deputy General Manager | Leadership |
Complete people profiles for Dong-A Socio Holdings
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dong-A Socio Holdings
Dong-A Socio Holdings is a publicly listed company on the KRX with ticker symbol 000640 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Oct 2010
- Listed onKRX: 000640
- Listed entityDong-A Socio Holdings Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7000640003
- Share price93,000.00 KRW (-1.8% on the day) · 2026-10-08
- Market capitalisation616,993,336,201.00 KRW
- Price to earnings7.3
- EPS (diluted, trailing year)12,763.81 KRW
- Dividend yield1.76%
- Volume (last session)7,552
Financials of Dong-A Socio Holdings
Figures of Dong-A St India Private Limited, the primary company behind Dong-A Socio Holdings, for FY 2025. Revenue was ₹2.08 Cr (-12% year on year). Net profit was ₹0.03 Cr (2% margin). EBITDA was ₹0.27 Cr (13% margin). Revenue has grown at a compounded annual rate of +27% over three years.
- ₹2.08 CrRevenue · FY 2025 · -12% YoY
- ₹0.03 CrNet profit · 2% margin
- ₹0.27 CrEBITDA · 13% margin
- ₹0.70 CrPaid-up capital
- +27%Revenue CAGR, 3 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1,430.00B KRW | 90.94B KRW | 193.15B KRW |
| 2024 | 1,330.00B KRW | 58.02B KRW | 171.33B KRW |
| 2023 | 1,130.00B KRW | 57.99B KRW | 151.05B KRW |
| 2022 | 1,010.00B KRW | 11.15B KRW | 108.59B KRW |
| 2021 | 881.94B KRW | 60.27B KRW | 120.94B KRW |
Balance sheet, profit and loss, cash flow and ratios of Dong-A St India Private Limited are on its company page.
Detailed financial statements for Dong-A Socio Holdings
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Dong-A Socio Holdings
Dong-A Socio Holdings operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and ALX Oncology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| regeneron.com | 1988 | Tarrytown, United States | – | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. |
Detailed competitors of Dong-A Socio Holdings
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dong-A Socio Holdings
The website of Dong-A Socio Holdings (donga.co.kr) receives about 17.1K visits a month and ranks #1,381,945 among all websites worldwide, #1,791 in Biotechnology and Pharmaceuticals.
- Monthly visits17.1K
▼ 4.7% vs previous month
- Unique visitors5.9K
per month
- Global rank#1,381,945
among all websites
- Category rank#1,791
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.2
- Average visit40 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Dong-A Socio Holdings. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kolonpharm.co.kr | 100% | – | #1,882,169 | View details | |
otsuka.co.kr | otsuka.co.kr | 92% | – | #3,119,421 | – |
dapharm.com | dapharm.com | 88% | – | #620,157 | – |
| novartis.com | 83% | 948.8K | #58,822 | View details | |
| roche.com | 83% | 1.3M | #42,219 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Dong-A Socio Holdings
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Dong-A Socio Holdings
Complete news archive for Dong-A Socio Holdings
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Dong-A Socio Holdings
10 companies that operate in the same segment as Dong-A Socio Holdings (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dong-A Socio Holdings
Dong-A Socio Holdings was founded in 1932.
Dong-A Socio Holdings is headquartered in Seoul, South Korea.
Matthew Han is the current CEO of Dong-A Socio Holdings.
Dong-A Socio Holdings has 82 employees.
The primary company behind Dong-A Socio Holdings, Dong-A St India Private Limited, reported revenue of ₹2.08 Cr for FY 2025, down 12% year on year.
Dong-A Socio Holdings was established in 1932 in Seoul, South Korea, within the biotechnology sector. Focus is placed on developing therapies for female infertility, with the lead product DA-3801a long-acting recombinant follicle stimulating hormonemarketed in Korea. Additional candidates are being advanced for conditions including neutropenia, anemia, breast cancer, rheumatoid arthritis, and psoriasis, supporting operations in pharmaceutical research and development.
Dong-A Socio Holdings's top competitors include Moderna, BeiGene and Strand Therapeutics.
Yes, Dong-A Socio Holdings is publicly traded on KRX under the ticker symbol 000640.
Dong-A Socio Holdings operates through Dong-A St India Private Limited.
The legal entities of Dong-A Socio Holdings currently have 2 directors, including Daewon Kwak, Sungkyu Park.